Lymphoma

In a small sample, retreatment of patients with large B-cell lymphoma showed good response, notably in patients who had complete response on initial treatment, according to a poster presented at ASCO 2020 Virtual Scientific Program.

A novel CAR T-cell therapy targeting both CD19 and CD22 showed less toxicities than current CAR T-cell therapies while producing complete response with accepted regimens, according to a study presented at ASCO2020 Virtual Scientific Program.

A literature review presented at the ASCO2020 Virtual Scientific Program showed the efficacy of high-dose chemotherapy in conjunction with allogeneic hematopoietic stem cell transplant in treating central nervous system lymphoma.

Though CAR T-cell therapy quickly became the standard of care in diffuse large B-cell lymphoma, a presenter at ASCO2020 Virtual Scientific Program suggested studies need to continue to look at autologous transplant.

The FDA granted accelerated approval to selinexor for treatment of adults with relapsed or refractory diffuse large B-cell lymphoma who received at least two prior lines of systemic therapy.

Anti-CD19 CAR-T cells led to highly durable remissions in chronic lymphocytic leukemia and B-cell lymphoma, according to data from the longest follow-up study of patients who received this treatment presented at ASCO20 Virtual Scientific Program.

The addition of rituximab to standard lymphomes malins B chemotherapy improved EFS and OS among a subset of pediatric patients with non-Hodgkin lymphoma, according to study results published in The New England Journal of Medicine.

An allogeneic chimeric antigen T-cell therapy plus an anti-CD52 monoclonal antibody appeared safe for certain patients with large B-cell or follicular lymphoma, according to study data presented during the ASCO20 Virtual Scientific Program.

Pembrolizumab extended PFS compared with brentuximab vedotin for patients with relapsed or refractory classic Hodgkin lymphoma, according to study results presented during the ASCO20 Virtual Scientific Program.

The various cognitive impairments collectively known as “chemo brain” can cause anxiety, frustration and difficulty with everyday tasks for cancer survivors.